These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33748950)

  • 21. Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Barnea Slonim L; Ma S; Behdad A; Chen Q
    Br J Haematol; 2020 Oct; 191(1):e22-e25. PubMed ID: 32677079
    [No Abstract]   [Full Text] [Related]  

  • 22. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
    Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
    Front Immunol; 2020; 11():2158. PubMed ID: 32983178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib.
    Marcaillou M; Stéphanie D; Marion B; Julien S; Christophe B
    Am J Dermatopathol; 2020 Dec; 42(12):1012-1014. PubMed ID: 32675466
    [No Abstract]   [Full Text] [Related]  

  • 24. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Visentin A; Mauro FR; Cibien F; Vitale C; Reda G; Fresa A; Ciolli S; Pietrasanta D; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Scarfò L; Sportoletti P; Pravato S; Piazza F; Coscia M; Laurenti L; Molica S; Foà R; Cuneo A; Trentin L
    Am J Hematol; 2022 Mar; 97(3):E95-E99. PubMed ID: 34904743
    [No Abstract]   [Full Text] [Related]  

  • 25. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Uncommon Cause of Ring-Enhancing Brain Lesion: Cerebral Aspergillosis.
    Bansal S; Singhania N; Yadav M; Chatterjee T
    Am J Med Sci; 2021 Jan; 361(1):140-141. PubMed ID: 32962800
    [No Abstract]   [Full Text] [Related]  

  • 27. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
    Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
    Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
    [No Abstract]   [Full Text] [Related]  

  • 28. Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia.
    Kaya A; Aras İ; Özkan Kurtgöz P; Çakıroğlu U
    Turk J Haematol; 2024 Mar; 41(1):57-58. PubMed ID: 38433497
    [No Abstract]   [Full Text] [Related]  

  • 29. Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Booth E; Backx M; Joshi A; Nizami H; Elmusharaf N
    Br J Haematol; 2023 Nov; 203(4):499-500. PubMed ID: 37696766
    [No Abstract]   [Full Text] [Related]  

  • 30. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
    Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
    Steingrímsson V; Gíslason GK; Þorsteinsdóttir S; Rögnvaldsson S; Gottfreðsson M; Aspelund T; Turesson I; Björkholm M; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Mar; 106(3):346-353. PubMed ID: 33211356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Pulido-Pérez A; Bergón-Sendín M; Mateos-Mayo A; Parra-Blanco V; Suárez-Fernández R; Carretero-López F
    Ann Hematol; 2021 Dec; 100(12):3065-3066. PubMed ID: 33026479
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
    Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
    Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
    J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
    Visentin A; Imbergamo S; Trimarco V; Pravato S; Romano Gargarella L; Frezzato F; Scapinello G; Bertorelle R; Piva E; Facco M; Semenzato G; Piazza F; Trentin L
    Hematol Oncol; 2020 Dec; 38(5):823-826. PubMed ID: 32979282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
    Ghez D; Calleja A; Protin C; Baron M; Ledoux MP; Damaj G; Dupont M; Dreyfus B; Ferrant E; Herbaux C; Laribi K; Le Calloch R; Malphettes M; Paul F; Souchet L; Truchan-Graczyk M; Delavigne K; Dartigeas C; Ysebaert L;
    Blood; 2018 Apr; 131(17):1955-1959. PubMed ID: 29437588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib induces multiple functional defects in the neutrophil response against
    Blez D; Blaize M; Soussain C; Boissonnas A; Meghraoui-Kheddar A; Menezes N; Portalier A; Combadière C; Leblond V; Ghez D; Fekkar A
    Haematologica; 2020; 105(2):478-489. PubMed ID: 31171644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
    Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
    Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.